An e-cigarette is a device which vaporises and delivers a chemical mixture known as an “e-liquid” to the lungs in the form of an aerosol. E-Liquids are typically composed of nicotine, propylene glycol and other chemicals. All e-cigarettes comprise of a lithium battery, a cartridge containing the e-liquid, an atomizer which heats the e-liquid to create the aerosol, and a mouth piece.

The design of e-cigarettes has changed considerably since products were first marketed in Europe in 2006. First-gen­eration devices resemble conventional cigarettes. These comprise low-capacity disposable or rechargeable batteries and combined cartridges and atomizers.

Second-generation devices resemble pens and use larger batteries and fluid-filled reservoirs (tanks), filled from bottles of e-liquid. Third-generation devices bear little resemblance to cigarettes, use larger-capacity batteries, replaceable heating coils and wicks for atomizers and adjustable and programmable power delivery.

E-liquids are available on the Irish market with nicotine strengths of 0, 3, 6, 9, 12, 18 and 20 milligrams (mg). It is also possible for users to create their own e-liquid by mixing 20mg “nicotine shots” with larger bottles of nicotine free e-liquid.

Irish Cancer Society position on e-cigarettes
E-cigarettes are less harmful than combustible cigarettes, but health risks remain. There is not enough evidence e-cigarettes are an effective quit aid for smokers; while other methods, such as Nicotine Replacement Therapy and prescription drugs have been proven to be effective in helping people to quit. There is a need for greater evidence on the long-term health consequences of e-cigarette use.

As a result of clever marketing, e-cigarette use is increasing among young people and may act as a gateway to smoking. Investment is needed in smoking cessation strategies we know will make a difference in supporting people to quit smoking...